JP2008520719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520719A5 JP2008520719A5 JP2007543334A JP2007543334A JP2008520719A5 JP 2008520719 A5 JP2008520719 A5 JP 2008520719A5 JP 2007543334 A JP2007543334 A JP 2007543334A JP 2007543334 A JP2007543334 A JP 2007543334A JP 2008520719 A5 JP2008520719 A5 JP 2008520719A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylamino
- hydrogen
- aryl
- alkoxy
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 131
- 229910052739 hydrogen Inorganic materials 0.000 claims 124
- 239000001257 hydrogen Substances 0.000 claims 122
- 125000003118 aryl group Chemical group 0.000 claims 93
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 82
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 79
- 125000001072 heteroaryl group Chemical group 0.000 claims 77
- 150000001875 compounds Chemical class 0.000 claims 69
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 67
- 125000000623 heterocyclic group Chemical group 0.000 claims 61
- 150000002431 hydrogen Chemical group 0.000 claims 54
- 125000005843 halogen group Chemical group 0.000 claims 52
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 43
- -1 amino, hydroxy Chemical group 0.000 claims 34
- 125000004093 cyano group Chemical group *C#N 0.000 claims 34
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 34
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 33
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 32
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 24
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 15
- 125000004404 heteroalkyl group Chemical group 0.000 claims 13
- 150000004677 hydrates Chemical class 0.000 claims 13
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 206010021143 Hypoxia Diseases 0.000 claims 12
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 11
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 11
- 230000007954 hypoxia Effects 0.000 claims 11
- 239000012190 activator Substances 0.000 claims 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 9
- 125000003435 aroyl group Chemical group 0.000 claims 8
- 229910052736 halogen Chemical group 0.000 claims 5
- 150000002367 halogens Chemical group 0.000 claims 5
- 150000002772 monosaccharides Chemical class 0.000 claims 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 4
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 claims 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical group [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000007717 exclusion Effects 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 125000001483 monosaccharide substituent group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000006553 hypoxic activation Effects 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 CCC1[C@@](**2(C)CCCC2)C1 Chemical compound CCC1[C@@](**2(C)CCCC2)C1 0.000 description 8
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63042204P | 2004-11-22 | 2004-11-22 | |
| US72692805P | 2005-10-14 | 2005-10-14 | |
| PCT/US2005/042095 WO2006057946A2 (en) | 2004-11-22 | 2005-11-17 | Tubulin binding anti cancer agents and prodrugs thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520719A JP2008520719A (ja) | 2008-06-19 |
| JP2008520719A5 true JP2008520719A5 (enExample) | 2009-01-22 |
Family
ID=36498450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543334A Withdrawn JP2008520719A (ja) | 2004-11-22 | 2005-11-17 | チューブリン結合抗癌剤およびそれらのプロドラッグ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090042820A1 (enExample) |
| EP (1) | EP1819338A4 (enExample) |
| JP (1) | JP2008520719A (enExample) |
| KR (1) | KR20070086595A (enExample) |
| AU (1) | AU2005309761A1 (enExample) |
| CA (1) | CA2587210A1 (enExample) |
| IL (1) | IL183212A0 (enExample) |
| MX (1) | MX2007006102A (enExample) |
| NO (1) | NO20073211L (enExample) |
| WO (1) | WO2006057946A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| CN102746336B (zh) | 2005-06-29 | 2015-08-19 | 施瑞修德制药公司 | 氨基磷酸酯烷化剂前体药物 |
| CA2655913A1 (en) * | 2006-06-28 | 2008-01-03 | Sanwa Kagaku Kenkyusho Co., Ltd. | Novel 6-5 system bicyclic heterocyclic derivative and its pharmaceutical utility |
| US8552048B2 (en) | 2006-12-26 | 2013-10-08 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs for the treatment of cancer |
| US8765690B2 (en) | 2007-04-05 | 2014-07-01 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with glufosfamide in patients not receiving insulin therapy |
| WO2008151253A1 (en) * | 2007-06-04 | 2008-12-11 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of antineoplastic agents |
| ES2884674T3 (es) | 2008-10-21 | 2021-12-10 | Immunogenesis Inc | Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed |
| FR2962437B1 (fr) * | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
| US9487506B2 (en) | 2011-04-13 | 2016-11-08 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| WO2014069063A1 (ja) | 2012-10-29 | 2014-05-08 | 京セラ株式会社 | 弾性表面波センサ |
| WO2015048553A1 (en) * | 2013-09-27 | 2015-04-02 | Allergan, Inc. | Compounds and methods for skin repair |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| NZ723203A (en) | 2014-02-13 | 2020-08-28 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| PH12020552066A1 (en) | 2014-02-13 | 2022-05-11 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016011195A1 (en) | 2014-07-17 | 2016-01-21 | Threshold Pharmaceuticals, Inc. | Th-302 solid forms and methods related thereto |
| TWI674258B (zh) | 2015-03-10 | 2019-10-11 | 大陸商深圳艾欣達偉醫藥科技有限公司 | Ｄｎａ烷化劑 |
| CN108136214B (zh) * | 2015-04-02 | 2020-08-28 | 深圳艾欣达伟医药科技有限公司 | 硝基苄基衍生物抗癌试剂 |
| TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
| CN108024974B (zh) | 2015-06-24 | 2023-11-14 | 免疫原公司 | 含有dna烷化剂的氮丙啶 |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| MX387322B (es) | 2016-04-22 | 2025-03-18 | Incyte Corp | Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1). |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US11427591B2 (en) * | 2018-10-17 | 2022-08-30 | Insilico Medicine Ip Limited | Kinase inhibitors |
| CN115403483B (zh) * | 2021-07-02 | 2024-01-26 | 河南省儿童医院郑州儿童医院 | 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004099139A1 (en) * | 2000-09-15 | 2004-11-18 | Baylor University | Indole-containing compounds with anti-tubulin and vascular targeting activity |
| JP2004505888A (ja) * | 2000-03-10 | 2004-02-26 | ベイラー・ユニバーシテイ | チューブリン結合リガンドおよび対応するプロドラッグ構造 |
| FR2816938B1 (fr) * | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| FR2839718B1 (fr) * | 2002-05-17 | 2004-06-25 | Sanofi Synthelabo | Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| EP1506960B1 (en) * | 2003-08-07 | 2011-04-06 | National Health Research Institutes | Indole compounds as inhibitors of tubulin polymerisation for the treatment of angiogenesis-related disorders |
| US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
-
2005
- 2005-11-17 EP EP05826480A patent/EP1819338A4/en not_active Withdrawn
- 2005-11-17 AU AU2005309761A patent/AU2005309761A1/en not_active Abandoned
- 2005-11-17 CA CA002587210A patent/CA2587210A1/en not_active Abandoned
- 2005-11-17 KR KR1020077014342A patent/KR20070086595A/ko not_active Withdrawn
- 2005-11-17 US US11/791,420 patent/US20090042820A1/en not_active Abandoned
- 2005-11-17 JP JP2007543334A patent/JP2008520719A/ja not_active Withdrawn
- 2005-11-17 WO PCT/US2005/042095 patent/WO2006057946A2/en not_active Ceased
- 2005-11-17 MX MX2007006102A patent/MX2007006102A/es not_active Application Discontinuation
-
2007
- 2007-05-15 IL IL183212A patent/IL183212A0/en unknown
- 2007-06-22 NO NO20073211A patent/NO20073211L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520719A5 (enExample) | ||
| JP2020505376A5 (enExample) | ||
| JP2008514610A5 (enExample) | ||
| RU2019126455A (ru) | Пиридиновые соединения в качестве аллостерических ингибиторов shp2 | |
| JP2018109017A5 (enExample) | ||
| KR20180105700A (ko) | 체크포인트 키나아제 1(chk1) 억제제로서 유용한 3,5-이치환된 피라졸, 및 이의 제조 및 적용 | |
| JP2001504109A (ja) | ベンゾ複素環ジスタマイシン誘導体、それらを製造する方法および抗腫瘍および抗ウイルス剤としてのそれらの用途 | |
| JP2014509647A5 (enExample) | ||
| RU2010137115A (ru) | Производные 5,6-бисарил-2-пиридинкарбоксамидов, способ их получения и их применение в терапии в качестве антагонистов рецепторов | |
| JP2017519754A5 (enExample) | ||
| JP2015522551A5 (enExample) | ||
| JP2018513832A5 (enExample) | ||
| JP2010520168A5 (enExample) | ||
| EA030569B1 (ru) | Замещенные бициклические дигидропиримидиноны и их применение в качестве ингибиторов активности нейтрофильной эластазы | |
| JPH03170482A (ja) | ３環性プテリジノン類及びその製造方法 | |
| RU2014152697A (ru) | Новые производные салициловой кислоты, их фармацевтически приемлемая соль, композиции и способ применения | |
| BR112014023957B1 (pt) | Compostos agonistas dos receptores adrenérgicos alfa-2 e composição farmacêutica que compreende os mesmos | |
| JP2015502371A5 (enExample) | ||
| UA61922C2 (uk) | Акрилоїлзаміщенa похідна дистаміцину, спосіб її одержання (варіанти) та фармацевтична композиція на її основі | |
| CA2931804A1 (en) | Piperidine and piperazine derivatives and their use in treating viral infections and cancer | |
| KR20130121857A (ko) | 다발성 골수종의 치료 효과를 갖는 피라졸 화합물 | |
| EP4201941B1 (en) | Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof | |
| EP2632916B1 (en) | Novel anti-cancer agents | |
| DK2991993T3 (en) | NEW MORPHOLINYLANTHRACYCLINE DERIVATIVES | |
| JPH07196511A (ja) | キノキサリンおよびヌクレオシドを含有する複合製剤 |